FDA backlog slows generic drug approval

CNNMoney explores the bottleneck at the FDA that is keeping generic drugs from competing with more expensive branded competitors. Over the next five years about $100 million in drugs will go off patent. But due to budget restrictions, the FDA's Office of Generic Drugs can only handle about 400 applications and approvals each year, accounting for only half of the backlog. This translates into less competition and larger profits for the branded drug makers.

- read this article [1] for more